

Sacituzumab govitecan ASCENT

PRELIMINARY SCORE

CURATIVE



NON-CURATIVE



ADJUSTMENTS

Quality of life



Improved QoL



Serious and disabling adverse effects



Other adjustments



Sacituzumab govitecan ASCENT

SCORE

CURATIVE



Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE



Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Therapeutic Indication: Treatment of patients with unresectable or metastatic TNBC who have received  $\geq 2$  prior systemic therapies,  $\geq 1$  of them for advanced disease  
Experimental Arm: Sacituzumab govitecan  
Control Arm: Physician's choice of single agent ChT

